Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

The South San Francisco company has enticed Gilead with its vision of using AI and machine learning to transform drug discovery, getting $15 million in upfront backing in a deal that could be ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.